ArticleAdvances in therapy2022

Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.

Shinya Rai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.